Hellstrom W.J., Feldman R., Rosen R.C. et al. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol 2013;190(2):627–34.
DOI: 10.1016/j.juro.2013.01.090
Tal R., Hall M.S., Alex B. et al. Peyronie’s disease in teenagers. J Sex Med 2012;9(1):302–8.
DOI: 10.1111/j.1743-6109.2011.02502.x
Stuntz M., Perlaky A., des Vignes F. et al. The prevalence of Peyronie’s disease in the United States: a population-based study. PloS One 2016;11(2):e0150157.
DOI: 10.1371/journal.pone.0150157
Moreno S.A., Morgentaler A. Testosterone deficiency and Peyronie’s disease: pilot data suggesting a significant relationship. J Sex Med 2009;6(6):1729–35.
DOI: 10.1111/j.1743-6109.2009.01250.x
Al-Thakafi S., Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol 2016;5(3):280–9.
DOI: 10.21037/tau.2016.04.05
Habous M., Malkawi I., Han E. et al. Peyronie’s disease is common in poorly controlled diabetics but is not associated with the metabolic syndrome. Urol Ann 2019;11(3):252–6.
DOI: 10.4103/UA.UA_164_18
Schneider D., Afyouni A.S., Yafi F.A. Peyronie’s disease and testosterone: a narrative review. Androg Clin Res Ther 2022;3(1):105–12.
DOI: 10.1089/andro.2021.0027
Can O., Özbir S., Atalay H.A. et al. The relationship between testosterone levels and Peyronie’s disease. Andrologia 2020;52(9):e13727.
DOI: 10.1111/and.13727
Ширин Г.В., Федорова Н.А. Болезнь Пейрони и первый опыт использования Пейрофлекса®. Вестник урологии 2021;9(2):150–6.
DOI: 10.21886/2308-6424-2021-9-2-150-156
Shindel A.W., Sweet G., Thieu W. et al. Prevalence of Peyronie’s disease-like symptoms in men presenting with Dupuytren contractures. Sex Med 2017;5(3):e135–e41.
DOI: 10.1016/j.esxm.2017.06.001
Akbal C., Tanidir Y., Ozgen M.B., Simşek F. Erectile dysfunction and Peyronie’s disease in patient with retroperitoenal fibrosis. Int Urol Nephrol 2008;40(4):971–5.
DOI: 10.1007/s11255-008-9381-4
Tal R., Heck M., Teloken P. et al. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med 2010;7(3):1254–61.
DOI: 10.1111/j.1743-6109.2009.01655.x
EAU Guidelines. Edn. presented at the EAU Annual Congress, Milan, 2023.
Krakhotkin D.V., Chernylovskyi V.A., Mottrie A. et al. New insights into the pathogenesis of Peyronie’s disease: a narrative review. Chronic Dis Transl Med 2020;6(3):165–81.
DOI: 10.1016/j.cdtm.2020.06.001
Herati A.S., Pastuszak A.W. The genetic basis of Peyronie disease: a review. Sex Med Rev 2016;4(1):85–94.
DOI: 10.1016/j.sxmr.2015.10.002
Gabrielsen J.S. Peyronie’s disease: is it genetic or not? Transl Androl Urol 2020;9(Suppl2):S262–S8.
DOI: 10.21037/tau.2019.10.21
Sharma K.L., Alom M., Trost L. The etiology of Peyronie’s disease: pathogenesis and genetic contributions. Sex Med Rev 2020;8(2): 314–23.
DOI: 10.1016/j.sxmr.2019.06.004
Dolmans G.H., Werker P.M., de Jong I.J. et al. WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. J Sex Med 2012;9(5):1430–4.
DOI: 10.1111/j.1743-6109.2012.02704.x
Sergovich F.R., Botz J.S., McFarlane R.M. Nonrandom cytogenetic abnormalities in Dupuytren’s disease. N Engl J Med 1983;308(3):162–3
Dal Cin P., De Smet L., Sciot R. et al. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren’s disease. Cancer Genet Cytogenet 1999;108(2):137–40.
DOI: 10.1016/s0165-4608(98)00126-5
Casalone R., Mazzola D., Meroni E. et al. Cytogenetic and interphase cytogenetic analyses reveal chromosome instability but no clonal trisomy 8 in Dupuytren contracture. Cancer Genet Cytogenet 1997;99(1):73–6.
DOI: 10.1016/s0165-4608(96)00430-x
Nyberg L.M. Jr., Bias W.B., Hochberg M.C. et al. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982;128(1):48–51.
DOI: 10.1016/s0022-5347(17)52751-2
Nugteren H.M., Nijman J.M., de Jong I.J., van Driel M.F. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res 2011;23(4):142–5.
DOI: 10.1038/ijir.2011.18
Allen-Brady K.L., Christensen M.B., Sandberg A.D., Pastuszak A.W. Significant familial clustering of Peyronie’s disease in close and distant relatives. Andrology 2022;10(7):1361–7.
DOI: 10.1111/andr.13223
Perinchery G., El-Sakka A.I., Angan A. et al. Microsatellite alterations and loss of heterozygosity in Peyronie’s disease. J Urol 2000;164(3 Pt 1):842–6.
DOI: 10.1097/00005392-200009010-00059
Qian A., Meals R.A., Rajfer J. et al. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 2004;64(2):399–404.
DOI: 10.1016/j.urology.2004.04.006
Gonzalez-Cadavid N.F., Magee T.R., Ferrini M. et al. Gene expression in Peyronie’s disease. Int J Impot Res 2002;14(5):361–74.
DOI: 10.1038/sj.ijir.3900873
Dullea A., Efimenko I., Firdaus F. et al. Whole-genome sequencing identifies novel heterozygous mutation in ALMS1 in three men with both Peyronie’s and Dupuytren’s Disease. Urology 2022;166:76–8.
DOI: 10.1016/j.urology.2022.02.023
Moses H.L., Roberts A.B., Derynck R. The discovery and early days of TGF-β: a historical perspective. Cold Spring Harbor Perspect Biol 2016;8(7):a021865.
DOI: 10.1101/cshperspect.a021865
Baba A.B., Rah B., Bhat G.R. et al. Transforming growth factor-beta (TGF-β) signaling in cancer – a betrayal within. Front Pharmacol 2022;13:791272.
DOI: 10.3389/fphar.2022.791272
Papageorgis P. TGFβ signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J Oncol 2015;2015:587193.
DOI: 10.1155/2015/587193
Hassoba H., El-Sakka A., Lue T. Role of increased transforming growth factor beta protein expression in the pathogenesis of Peyronie’s disease. Egypt J Immunol 2005;12(1):1–8
Piao S., Choi M.J., Tumurbaatar M. et al. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie’s plaque. J Sex Med 2010;7(10):3385–95.
DOI: 10.1111/j.1743-6109.2010.01753.x
Wang J., Xiang H., Lu Y., Wu T. Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med 2021;47(4):55.
DOI: 10.3892/ijmm.2021.4888
Biernacka A., Dobaczewski M., Frangogiannis N.G. TGF-β signaling in fibrosis. Growth Factors (Chur, Switzerland) 2011;29(5):196–202.
DOI: 10.3109/08977194.2011.595714
Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med 2020;217(3):e20190103.
DOI: 10.1084/jem.20190103
Eftimie R., Brenner H.R., Buonanno A. Myogenin and MyoD join a family of skeletal muscle genes regulated by electrical activity. Proc Natl Acad Sci U S A 1991;88(4):1349–53.
DOI: 10.1073/pnas.88.4.1349
Cantini L.P., Ferrini M.G., Vernet D. et al. Profibrotic role of myostatin in Peyronie’s disease. J Sex Med 2008;5(7):1607–22.
DOI: 10.1111/j.1743-6109.2008.00847.x
Chen M.M., Zhao Y.P., Zhao Y. et al. Regulation of myostatin on the growth and development of skeletal muscle. Front Cell Dev Biol 2021;9:785712.
DOI: 10.3389/fcell.2021.785712
Beutel B., Song J., Konken C.P. et al. New in vivo compatible matrix metalloproteinase (MMP)-2 and MMP-9 inhibitors. Bioconjug Chem 2018;29(11):3715–25.
DOI: 10.1021/acs.bioconjchem.8b00618
Bormann T., Maus R., Stolper J. et al. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice. Respir Res 2022;23(1):180.
DOI: 10.1186/s12931-022-02105-7
Cohen D.J., Reynaldo W.V., Borba V.B. et al. New in vivo model to assess macroscopic, histological, and molecular changes in Peyronie’s disease. Andrology 2022;10(1):154–65.
DOI: 10.1111/andr.13092
Rompel R., Mueller-Eckhardt G., Schroeder-Printzen I. et al. HLA antigens in Peyronie’s disease. Urol Int 1994;52(1):34–7.
DOI: 10.1159/000282566
Cushing L., Kuang P.P., Qian J. et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45(2):287–94.
DOI: 10.1165/rcmb.2010-0323OC
Dos Santos V.G., Dos Santos G.A., Neto C.B. et al. Downregulation of miR-29b is associated with Peyronie’s disease. Urologia 2022;89(3):451–5.
DOI: 10.1177/03915603211036628
Ten Dam E.P.M., van Driel M.F., de Jong I.J. et al. Glimpses into the molecular pathogenesis of Peyronie’s disease. Aging Male 2020;23(5):962–70.
DOI: 10.1080/13685538.2019.1643311
De Young L.X., Bella A.J., O’Gorman D.B. et al. Protein biomarker analysis of primary Peyronie’s disease cells. J Sex Med 2010;7(1 Pt 1):99–106.
DOI: 10.1111/j.1743-6109.2009.01556.x
Weis M.A., Hudson D.M., Kim L. et al. Location of 3-hydroxyproline residues in collagen types I, II, III, and V/XI implies a role in fibril supramolecular assembly. J Biol Chem 2010;285(4):2580–90.
DOI: 10.1074/jbc.M109.068726
Stone R.C., Pastar I., Ojeh N. et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res 2016;365(3):495–506.
DOI: 10.1007/s00441-016-2464-0
Сабирзянова А.А., Галявич А.С., Балеева Л.В. и др. Прогностическое значение фактора дифференцировки роста-15 у пациентов с инфарктом миокарда. Российский кардиологический журнал 2021;26(2):4288.
DOI: 10.18087/cardio.2023.2.n2152
Кукес В.Г., Газданова А.А., Фуралев В.А. и др. Современное представление о биологической роли и клиническом значении миостатина – главного регулятора роста и дифференцировки мышц. Медицинский вестник Северного Кавказа 2021;16(3):327–32.
Гервальд В.Я., Привалихина А.В., Спицын П.С. и др. Болезнь Пейрони как фактор эректильной дисфункции. Механизмы фиброза. Современные проблемы науки и образования 2017;4https://science-education.ru/ru/article/view?id=26654
Willscher M.K., Cwazka W.F., Novicki D.E. The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol 1979;122(1):34–5.
DOI: 10.1016/s0022-5347(17)56238-2
Ralph D.J., Schwartz G., Moore W. et al. The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997;157(1):291–4.
DOI: 10.1016/S0022-5347(01)65362-X